Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging

Table 2 Patients’ survival according to Barcelona Clinic Liver Cancer, alpha-fetoprotein level and ascites

		1-yr survival	2-yr survival	3-yr survival	Median survival (mo)	P value
BCLC	A (n = 496)	90%	69%	56%	37	< 0.001
	B (n = 564)	69%	33%	18%	19
AFP	< 200 ng/mL (n = 652)	85%	59%	50%	33	< 0.001
	≥ 200 ng/mL (n = 408)	71%	41%	22%	21
Ascites	Absent (n = 818)	83%	58%	44%	31	< 0.001
	Present (n = 242)	69%	29%	23%	19

P < 0.05 is considered significant. AFP: Alpha-fetoprotein; BCLC: Barcelona Clinic Liver Cancer.